A diagnostic finding that had clinical management implications beyond epilepsy care (secondary findings) was described in 3–4 % of individuals, for example a (likely) pathogenic variant in BRCA2 which is associated with a higher risk for breast and ovarian cancer [8], [9]. The gene discussed is BRCA2; the disease is epilepsy.